- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01636635
Effect of Age and Weight Loss on Inflammation and Iron Homeostasis (HEP)
12. november 2015 oppdatert av: Simin Meydani, Tufts University
Effect of Age and Weight Loss on Obesity-related Inflammation and Iron Homeostasis in Women
The purpose of this study is to evaluate the effect of aging and weight loss on iron status and immune response in obese women.
Iron deficiency and immune impairment are two of the numerous complications of obesity.
The central hypothesis is that obesity-induced inflammation causes lower iron status through decreased iron absorption and availability in young and older obese women.
Furthermore, the investigators hypothesize that this can be corrected with weight loss in both young and older obese women.
Studieoversikt
Detaljert beskrivelse
Obese individuals have chronic inflammation, higher risk of iron deficiency, and impaired immune response.
These are conditions seen also with aging, but it is unknown to what extent they may be further impacted by obesity in the elderly.
With this study the investigators aim to establish the mechanism by which weight loss may reduce inflammation and enhance iron status in young and older obese adults through the peptide hormone hepcidin, which regulates iron homeostasis.
The investigators also aim to identify a possible link between iron homeostasis and immune response through hepcidin, which has been implicated in T cell mediated immunity.
The investigators hypothesize that obesity-induced inflammation causes dysregulation of hepcidin expression leading to lower iron status through decreased iron absorption and availability in young and older adults.
Furthermore, the investigators hypothesize that hepcidin dysregulation, and thus iron status can be mitigated with weight loss in both young and older obese adults.
This hypothesis will be tested in obese young and older women undergoing weight loss through calorie restriction.
Change in iron status, inflammation, and hepcidin will be determined before and after weight loss.
Further, the impact of inflammatory environment of obesity on peripheral blood mononuclear cell hepcidin, ferroportin, intracellular iron, and T cell function in young and older adults will be determined.
This study will address two important public health problems, i.e. obesity and iron deficiency and will be an important step toward the identification of strategies to enhance health of obese young and older adults.
Studietype
Intervensjonell
Registrering (Faktiske)
44
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02111
- JM USDA Human Nutrition Research Center on Aging
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion Criteria:
- Enrolling patients in the Weight and Wellness Center (WWC) at Tufts Medical Center, part of their Tufts Employees, low calorie diet (LCD) or pre-surgical low calorie diet (PS-LCD) program, or enrolling at WWC as individual patients.
- BMI in the range of 30 to 55 kg/m2.
- Either ages 18-45 or >60.
Exclusion Criteria:
- Pregnancy.
- Weight reduction greater than or equal to 3% in the past 3 months.
- Prior gastric restrictive surgery.
- Weight loss medications within the 4 weeks prior to screening.
- History of eating disorder.
- Renal disease (serum creatinine >2mg/dl).
- Hepatic disease, except for nonalcoholic steatohepatitis (NASH).
- Celiac disease, or any kind of intestinal malabsorption disorders.
- Gastrointestinal cancer.
- Hereditary hemochromatosis, or any blood disorders.
- Chronic infectious or inflammatory disease.
- Use of immunosuppressants.
- Severe iron deficiency anemia (hemoglobin<8 g/dl) or other conditions that would prevent them from discontinuing iron supplement use.
- Unwilling to discontinue iron supplement intake. The dietary plan recommended by the WWC will include daily intake of iron that meets the iron RDA for the subject's gender and age group, therefore discontinuing iron supplement will not be harmful for the participants. Intake of other supplements will not be an exclusion criteria, as long as it stays constant throughout the study period.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Young (18-45 years)
Obese young women (18-45y) undergoing calorie restriction.
|
Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
|
|
Eksperimentell: Older (>60 years)
Obese older women (>60y) undergoing calorie restriction.
|
Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in serum hepcidin
Tidsramme: Baseline and 12-16 weeks
|
The investigators will determine the change in hepcidin at baseline and after 12-16 weeks of calorie restriction.
|
Baseline and 12-16 weeks
|
|
Change in inflammation (CRP, IL-6)
Tidsramme: Baseline and 12-16 weeks
|
The investigators will determine the change in inflammation at baseline and after 12-16 weeks of calorie restriction.
|
Baseline and 12-16 weeks
|
|
Change in iron status
Tidsramme: Baseline and 12-16 weeks
|
The investigators will determine the change in iron status at baseline and after 12-16 weeks of calorie restriction.
|
Baseline and 12-16 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in PBMC intracellular iron content
Tidsramme: Baseline and 12-16 weeks
|
Baseline and 12-16 weeks
|
|
|
Change in PBMC Hepcidin expression
Tidsramme: Baseline and 12-16 weeks
|
Baseline and 12-16 weeks
|
|
|
Change in PBMC ferroportin expression
Tidsramme: Baseline and 12-16 weeks
|
Baseline and 12-16 weeks
|
|
|
Change in PBMC subpopulations and proliferation
Tidsramme: Baseline and 12-16 weeks
|
After stimulation with ConA, PHA and anti-CD3/CD28
|
Baseline and 12-16 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Simin N Meydani, DVM, PhD, Tufts University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mars 2011
Primær fullføring (Faktiske)
1. november 2013
Studiet fullført (Faktiske)
1. november 2013
Datoer for studieregistrering
Først innsendt
26. januar 2012
Først innsendt som oppfylte QC-kriteriene
5. juli 2012
Først lagt ut (Anslag)
10. juli 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
16. november 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
12. november 2015
Sist bekreftet
1. november 2015
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2765
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Calorie Restriction
-
Eastern Mediterranean UniversityFullførtMuskelstyrke | Muskelhypertrofi | SportsytelseKypros
-
Mayo ClinicFullført
-
Lauren EricksonAmerican College of Sports MedicineFullførtPatellofemoralt syndromForente stater
-
The Methodist Hospital Research InstituteRekrutteringSunn | Friske Frivillige | Friske mannlige og kvinnelige emnerForente stater
-
The Hong Kong Polytechnic UniversityHar ikke rekruttert ennåSarkopeni | Pasienter med kronisk hjerneslagHong Kong
-
West China HospitalHar ikke rekruttert ennåSarkopeni hos eldre
-
AspetarRekrutteringPatellofemoralt smertesyndrom | Kronisk knesmerter | Rotator cuff tendinose | Rotator Cuff Impingement Syndrome | Fremre knesmerter syndromQatar
-
Barzilai Medical CenterTel Aviv Medical Center; Israel Society of PulmonologyPåmelding etter invitasjon
-
Udayana UniversityFullførtSunne fag | Sport nivå 1Indonesia
-
Cairo UniversityAktiv, ikke rekrutterendeCerebral parese Spastisk hemiplegiskEgypt